NCT00022529View on ClinicalTrials.gov

BMS-214662 Plus Trastuzumab in Treating Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

July 31, 2001

Primary Completion Date

January 31, 2004

Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
DRUG

BMS-214662

Given IV

BIOLOGICAL

trastuzumab

Given IV

OTHER

pharmacological study

Correlative studies

Trial Locations (1)

19111-2497

Fox Chase Cancer Center, Philadelphia

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00022529 - BMS-214662 Plus Trastuzumab in Treating Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter